• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Werewolf Therapeutics Inc (NQ: HOWL )

    1.875 -0.015 (-0.79%)
    Streaming Delayed Price Updated: 10:36 AM EDT, Oct 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,315
    Open 1.880
    Bid (Size) 1.860 (6)
    Ask (Size) 1.890 (6)
    Prev. Close 1.890
    Today's Range 1.850 - 1.900
    52wk Range 1.573 - 8.194
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -59.59%
    -59.59%
    1 Month
    -11.97%
    -11.97%
    3 Month
    -19.87%
    -19.87%
    6 Month
    -64.95%
    -64.95%
    1 Year
    -9.86%
    -9.86%

    More News

    Read More
    HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Where Werewolf Therapeutics Stands With Analysts
    Via Benzinga
    Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
    Via Benzinga
    Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
    Via Benzinga
    Recap: Werewolf Therapeutics Q4 Earnings
    Via Benzinga
    Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.